These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10844105)

  • 21. Cardiac effects of moxonidine in spontaneously hypertensive obese rats.
    Mukaddam-Daher S; Menaouar A; El-Ayoubi R; Gutkowska J; Jankowski M; Velliquette RA; Ernsberger P
    Ann N Y Acad Sci; 2003 Dec; 1009():244-50. PubMed ID: 15028594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sympathoinhibitory mechanism of moxonidine: role of the inducible nitric oxide synthase in the rostral ventrolateral medulla.
    Peng J; Wang YK; Wang LG; Yuan WJ; Su DF; Ni X; Deng XM; Wang WZ
    Cardiovasc Res; 2009 Nov; 84(2):283-91. PubMed ID: 19535378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential changes in sympathetic activity in left and right ventricles in congestive heart failure after myocardial infarction.
    Ganguly PK; Dhalla KS; Shao Q; Beamish RE; Dhalla NS
    Am Heart J; 1997 Mar; 133(3):340-5. PubMed ID: 9060804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of the sympathoinhibition produced by the clonidine-like drugs rilmenidine and moxonidine.
    Szabo B; Bock C; Nordheim U; Niederhoffer N
    Ann N Y Acad Sci; 1999 Jun; 881():253-64. PubMed ID: 10415923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure.
    Yoshida H; Takahashi M; Tanonaka K; Maki T; Nasa Y; Takeo S
    Br J Pharmacol; 2001 Sep; 134(1):150-60. PubMed ID: 11522607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
    Swedberg K; Bristow MR; Cohn JN; Dargie H; Straub M; Wiltse C; Wright TJ;
    Circulation; 2002 Apr; 105(15):1797-803. PubMed ID: 11956122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological analysis of the cardiac sympatho-inhibitory actions of moxonidine and agmatine in pithed spontaneously hypertensive rats.
    Cobos-Puc LE; Sánchez-López A; Centurión D
    Eur J Pharmacol; 2016 Nov; 791():25-36. PubMed ID: 27565220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat.
    Gan XT; Ettinger G; Huang CX; Burton JP; Haist JV; Rajapurohitam V; Sidaway JE; Martin G; Gloor GB; Swann JR; Reid G; Karmazyn M
    Circ Heart Fail; 2014 May; 7(3):491-9. PubMed ID: 24625365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats.
    Louhelainen M; Vahtola E; Forsten H; Merasto S; Kytö V; Finckenberg P; Leskinen H; Kaheinen P; Tikkanen I; Levijoki J; Mervaala E
    J Hypertens; 2009 Oct; 27(10):2094-107. PubMed ID: 19730126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sympathoexcitation of moxonidine in the caudal ventrolateral medulla is dependent on I1-imidazoline receptors in anesthetized rats.
    Wang LG; Gao L; Wang W; Yuan WJ; Wang WZ
    Neurosci Lett; 2007 Oct; 426(2):91-6. PubMed ID: 17889438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin B-receptors and sympathetic activation: impact on ventricular arrhythmogenesis during acute myocardial infarction.
    Kolettis TM; Oikonomidis DL; Baibaki ME; Barka E; Kontonika M; Tsalikakis DG; Papalois A; Kyriakides ZS
    Life Sci; 2014 Nov; 118(2):281-7. PubMed ID: 24503339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure.
    Dickstein K; Manhenke C; Aarsland T; McNay J; Wiltse C; Wright T
    Int J Cardiol; 2000 Sep; 75(2-3):167-76; discussion 176-7. PubMed ID: 11077130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Total and high molecular weight adiponectin levels in the rat model of post-myocardial infarction heart failure.
    Kalisz M; Baranowska B; Wolinska-Witort E; Maczewski M; Mackiewicz U; Tulacz D; Gora M; Martynska L; Bik W
    J Physiol Pharmacol; 2015 Oct; 66(5):673-80. PubMed ID: 26579573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α2A-adrenoceptors, but not nitric oxide, mediate the peripheral cardiac sympatho-inhibition of moxonidine.
    Cobos-Puc LE; Aguayo-Morales H; Silva-Belmares Y; González-Zavala MA; Centurión D
    Eur J Pharmacol; 2016 Jul; 782():35-43. PubMed ID: 27112661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Restored capillary density in spared myocardium of infarcted rats improves ischemic tolerance.
    Van Kerckhoven R; Saxena PR; Schoemaker RG
    J Cardiovasc Pharmacol; 2002 Sep; 40(3):370-80. PubMed ID: 12198323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive responses elicited by central moxonidine in rats: possible role of nitric oxide.
    Moreira TS; Takakura AC; Sato MA; Menani JV; Colombari E
    J Cardiovasc Pharmacol; 2006 Jun; 47(6):780-7. PubMed ID: 16810079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the peripheral sympathetic nervous system in the natriuresis following central administration of an I1 imidazoline agonist, moxonidine.
    Penner SB; Smyth DD
    Br J Pharmacol; 1995 Nov; 116(6):2631-6. PubMed ID: 8590981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic imidazoline receptor activation in spontaneously hypertensive rats.
    Menaouar A; El-Ayoubi R; Jankowski M; Gutkowska J; Mukaddam-Daher S
    Am J Hypertens; 2002 Sep; 15(9):803-8. PubMed ID: 12219876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of alpha 2-adrenoceptors in the cardiovascular effects of moxonidine.
    Urban R; Szabo B; Starke K
    Eur J Pharmacol; 1995 Aug; 282(1-3):19-28. PubMed ID: 7498275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.